Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer
May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has …
Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer Read more »